research reports and media, page-2069

Further to the above post if you watch the vidio from 45min to 63min you will get a good overview on what its driving 008 and its significance to PAR.
As mentioned previously this is really a label study for post Phase 3 to be able to prove disease modificaton (for the commercialisation label) which takes IPPS to anther level in terms of price (as its not just a pain reduction med but a solution to OA). They are looking for bio-markers from day 56 to day 165.
Heres were we need clarity as he has stated that 008 Primary readout is Q3 (so thats the disease modifing aspect). The secondary being WOMAC pain and function is Q2 2022.

So ... if there has been any major divergence from this timeline we should have comms from them. I belive we are due an update this quarter (which is Q3). Does anybody know can they release preliminary findings without completing all the patients? You would have thought there would be a logical reasoning for choosing 60 patients initially so do reduce this seems illogical.

poolboy.

ps.. yes Im bored.